GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 04:42:52 03/07/2024 pm IST 5-day change 1st Jan Change
1,503 GBX -0.02% Intraday chart for GSK plc -6.00% +3.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights for Up to $1.56 Billion -- 2nd Update DJ
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits MT
GSK to Buy CureVac's Covid-19, Flu Vaccine Rights in Up to $1.56 Billion Deal -- Update DJ
CureVac Enters Into New Licensing Agreement With GSK; to Implement 'Significant' Restructuring; Shares Rise Pre-Bell MT
GSK inks licensing deal with CureVac for flu and Covid drugs AN
GSK: collaboration with CureVac in vaccines evolves CF
GSK, CureVac Expand Licensing Agreement DJ
Keywords Studios agrees takeover by EQT AN
GSK and CureVac to Restructure Collaboration into New Licensing Agreement CI
GSK Signs New Licensing Deal With CureVac for Influenza, Covid-19 Vaccines MT
Gsk PLC - Gsk And Curevac Collaboration Restructured RE
GSK buys full rights to make COVID, influenza vaccines from CureVac RE
Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount MT
GSK : Jefferies maintains a Buy rating ZD
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits MT
FTSE 100 slides as election looms, Sainsbury falls RE
London stocks slip as election looms closer, Sainsbury falls on reaffirmed outlook RE
GSK : JP Morgan keeps a Sell rating ZD
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge RE
GSK : Goldman Sachs remains Neutral ZD
New semester, new state of mind Our Logo
Analysis-Scientists wary of bird flu pandemic 'unfolding in slow motion' RE
GSK Settles Zantac Litigation in Illinois, US MT
GSK reaches settlement over Zantac case in Illinois AN
GSK Reaches Settlement in Illinois Zantac Lawsuit DJ
Chart GSK plc
More charts
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.04 GBP
Average target price
20.28 GBP
Spread / Average Target
+34.91%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. GSK Settles Zantac Litigation in Illinois, US